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Abstract
Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. Chromosomal instability (CIN) is a major
driving force of microsatellite stable (MSS) sporadic CRC. CIN tumours are characterised by a large number of
somatic chromosomal copy number aberrations (SCNA) that frequently affect oncogenes and tumour suppressor
genes. The main aim of this work was to identify novel candidate CRC driver genes affected by recurrent and focal
SCNA. High resolution genome-wide comparative genome hybridisation (CGH) arrays were used to compare tumour
and normal DNA for 53 sporadic CRC cases. Context corrected common aberration (COCA) analysis and custom
algorithms identified 64 deletions and 32 gains of focal minimal common regions (FMCR) at high frequency (>10%).
Comparison of these FMCR with published genomic profiles from CRC revealed common overlap (42.2% of
deletions and 34.4% of copy gains). Pathway analysis showed that apoptosis and p53 signalling pathways were
commonly affected by deleted FMCR, and MAPK and potassium channel pathways by gains of FMCR. Candidate
tumour suppressor genes in deleted FMCR included RASSF3, IFNAR1, IFNAR2 and NFKBIA and candidate
oncogenes in gained FMCR included PRDM16, TNS1, RPA3 and KCNMA1. In conclusion, this study confirms some
previously identified aberrations in MSS CRC and provides in silico evidence for some novel candidate driver genes.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in
males and the second in females [1]. More than 1 million new
CRC cases are diagnosed annually and ~600,000 related
deaths were estimated worldwide in the year 2008, making
CRC the 3rd highest cause of cancer related death in both
genders [1,2]. Chromosomal instability (CIN) is the most
common form of genomic instability in CRC and it is associated
with 65-85% of sporadic CRC cases [3–6]. Tumours that
develop through the CIN pathway are characterised by
frequent numerical and/or structural gains and losses of
chromosomal segments or whole chromosomes at a
significantly increased rate in comparison to normal cells [7].
CIN tumours are known to be associated with TP53 mutations
and low levels of microsatellite instability (MSI) [8,9]. CIN is
thought to drive CRC development through copy number gain
of oncogenes such as MYC and the deletion of tumour
suppressor genes such as SMAD4 and TP53 [3,9–13]. This
view is supported by the association observed between copy
number abnormalities of cancer-related genes, and their
expression levels in CRC samples [14–16].
Although most of the chromosomal aberrations arise in a
random fashion, some are recurrent and are commonly found
in other types of cancer in addition to CRC [13,16,17]. The
increased frequency of some somatic copy number aberrations
(SCNA) is probably a result of clonal selection during tumour
development. Recurrent SCNA provide the tumour with a way
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of targeting tumour suppressor genes and oncogenes to
acquire one or more of the cancer hallmarks and drive
tumorigenesis [13]. Several common chromosomal
abnormalities have been identified through conventional
cytogenetic techniques, such as metaphase comparative
genome hybridisation (CGH) and fluorescent in situ
hybridisation (FISH) [18–20]. These chromosomal defects
include gains of 8q, 13q and 20q and losses of 18q, 5q, 8p,
17q [18,20]. However, due to their large size, identification of
specific driver genes within these regions is problematic
[16,17,21].
The use of array-based CGH allows the acquisition of
genome-wide information with high resolution (down to a few
kilobases) and the identification of focal and minimal common
regions (FMCR) [16,17]. FMCR are usually smaller than 3Mb in
size and thus contain a relatively small number of genes,
hence simplifying the identification of driver genes [16,17].
Recently, FMCR have led to the identification of novel cancer
driver genes with potential therapeutic and prognostic value in
several cancer types including CRC [16,17,22–27]. The main
aim of this work was to apply a number of analytical
approaches based on high-resolution array-based CGH data
for a set of sporadic microsatellite stable (MSS) CRC tumours
to both replicate observations of aberrations identified in




Subjects gave written informed consent for data and sample
collection and the study was approved by South Yorkshire
Research Ethics Committee (UK) (09/H1310/54).
Study subjects and DNA samples
Tissue samples were available from 53 patients with MSS
colorectal tumours. Thirty-eight of these were undergoing
surgery for a primary colorectal tumour at the Sheffield Royal
Hallamshire and the Sheffield Northern General hospitals
(March, 2001 – June, 2005). Fifteen of the case tissue samples
were from Sheffield Royal Hallamshire Hospital tissue bank
(HTA License 12182). Before inclusion in the study, the tumour
status of all the samples was confirmed by a pathologist (JB).
All tumour tissue samples were micro-dissected prior to DNA
extraction, such that the extracted material contained at least
80% cancerous cells. DNA samples from peripheral blood or
normal colon tissues were also available from all of the
recruited patients. Additional data including; gender, tumour
location, degree of differentiation, stage and age of diagnosis
were available from the pathology records (Materials and
Methods S1). Genomic DNA was extracted from the tumour,
normal tissue and peripheral blood samples using the QIAamp
DNA Minikit, (Quiagen, Hilden, Germany).
MSI status
The MSI status of all the tumour DNA samples was
determined using the MSI Analysis System kit, v1.2 (Promega,
Madison, USA), based on the mononucleotide microsatellite
markers BAT-25, BAT-26, NR-21, NR-24 and MONO-27. PCR
products were separated by capillary electrophoresis using an
ABI PRISMTM 3730 DNA Analyser and analysed using
genemapper software v4.0 (Applied Biosystems, Warrington,
UK). Samples without any unstable markers were classified as
MSS [28]. The MSI analysis kit also includes 2 highly
polymorphic penta-nucleotide markers that were used to check
sample identity.
Sequencing and mutation analysis
For mutation analysis of BRAF exon 15, KRAS exon 2, APC
mutation cluster region (MCR), TP53 exons 4-9 and PIK3CA
exons 9 and 12, the respective exons were PCR amplified
(Primer sequences listed in Materials and Methods S1), and
sequenced using PRISMTM BigDye Terminator v3.1 standard
prototcol (Applied Biosystems). Sequence data were analysed
using the software STADEN [29] and mutations were confirmed
by comparison with the NCBI reference sequence. Accession
numbers are provided in Materials and Methods S1.
aCGH profiling
Agilent whole genome CGH arrays 4x44K (Design ID
014950) and 4x180K (Design ID 022060) were applied on 6
and 47 samples respectively (Agilent Technologies, Santa
Clara, CA, USA). The arrays contained 60-mer
oligonucleotides probes for 42,494 (44K) and 170,334 (180K)
distinct chromosomal locations with median probe spacing of
43kb (44K) and 13kb (180K). Analyses were performed
according to Agilent oligonucleotide array-based CGH protocol
v6.0. Quality assessment of the arrays was based on the
derivative log ratio spread (DLRS), signal intensity and
reproducibility, background noise, array grid placement and
outlier probes presented by Agilent feature extraction software
(v 10.5.1.1) as 11 well defined QC metrics (Microarray data
access information: GSE 418413).
Array CGH data analysis
The aCGH analysis was performed using the Agilent
genomic workbench software (v 5.0.14). SCNA were detected
using the quality weighted interval score algorithm, also called
the aberration detection method 2 (ADM2) algorithm
(Threshold: 6.0) with default centralisation and fuzzy zero
correction. Default feature and aberration filters were applied
and intra-array probe replicates were combined. Tumour
samples were considered chromosomally unstable if one or
more significant aberrations were identified [8]. Recurrent
SCNA were identified using the context corrected common
aberration (COCA) algorithm with a chromosomal scope, a p-
value of 0.05 and overlap threshold of 9.0.
FMCR were defined as regions that are less than 3Mb in size
and defined by at least 2 independent focal or overlapping
SCNA (considered as size determining events (SDE)). A
minimum frequency of >10% of the cases and a COCA score
of ~2.0 (p-value=0.01) were also required.
Candidate Driver Genes in Colorectal Cancer
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Technical validation
In order to validate the aCGH results, 2 duplicate
experiments using 44K and 180K arrays were performed.
Moreover, 3 FMCR (2 deleted and 1 amplified) were confirmed
using copy number quantitative PCR. TP53 LOH analysis
based on the sequencing results was used to confirm 17p
deletions.
Results
CIN, MSI and mutation status
The 53 samples selected for this study were MSS. The
analysis of APC, TP53, KRAS, BRAF and PIK3CA mutations
indicated that the frequency and pattern of these mutations
agree with previously published data on MSS sporadic CRC
[30–33] and (http://www-p53.iarc.fr/index.html). Of the 53 CRC
cases successfully analysed by array CGH, 5 had no
significant aberrations and were considered chromosomally
stable. The ADM2 algorithm failed to call aberrations for 2
samples and a further sample failed on >4 QC metrics. A
summary of the molecular features of the 53 samples is
presented in Table S1 in File S1.
Distribution of Common SCNA
A total of 3097 SCNA were identified in the 45
chromosomally unstable cases. The number of SCNA per
sample ranged from 1-411, with median of 43 per sample.
SCNA ranged in size from 0.014Mb-147.48Mb (median:
2.29Mb). An overview of the pattern and frequencies of these
SCNA is presented in Figure 1. The most common gains were
on chromosome regions 20q (73.3%, n=33), 13 (57.8%, n=26),
8q (53.3%, n=24), 7 (51.1%, n=23) and X (51.1%, n=23) and
the most common deletions were carried on chromosome
regions 18 (55.6%, n=25), 8p (51.1%, n=23) and 17p (51.1%,
n=23). Some of these regions contain key CRC driver genes,
such as MYC at 8q, SMAD4 at 18q and TP53 at 17p. A
summary of the SCNA for each sample is presented in Table
S1 in File S1 and Figure 2.
Common aberration analysis and FMCR
Out of the 3097 SCNA identified in the 45 chromosomally
unstable samples, 1689 aberrations were focal (<3.0Mb)
ranging in size from 0.014Mb up to 3.00Mb (median: 0.71Mb).
The focal aberrations consisted of 746 copy gains with a size
range of 0.014Mb-2.99Mb (median: 0.92Mb) and 943 deletions,
with a size range of 0.025Mb-3.00 Mb (median: 0.58Mb). To
identify FMCR, COCA analysis combined with the definitions
described in the Methods were applied on the ADM-2 output
and this analysis resulted in the identification of 64 deletions
and 32 gains meeting the FMCR criteria. The 64 deleted FMCR
ranged in size between 0.03-2.64Mb (median: 0.42Mb) and
contained a total of 714 known genes with a range of 0-69
genes deleted per region (median: 4 genes) (Table S2 in File
Figure 1.  Distribution of CNA in 40 CIN tumour samples.  Data from the 180K format array are shown. Red represents gains
and green represents deletions. The y-axis reflects frequency.
doi: 10.1371/journal.pone.0083859.g001
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Figure 2.  CNA identified in 40 CIN tumour samples (180K format array).  Representation of all the CNA identified in 40
chromosomally unstable cases analysed using the 180K platform. Red represents gain and green represents deletion. Dotted lines
mark centromeres. Molecular and clinical features in order from top; PIK3CA, APC, TP53, KRAS and BRAF mutation status (blue
and white represents mutant and WT respectively), CIMP (red, orange and green represent CIMP-H, CIMP-L and CIMP-N
respectively), patient’s gender (pink and grey represent female and male respectively) and tumour location (yellow and cyan
represent proximal and distal respectively).
doi: 10.1371/journal.pone.0083859.g002
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S1). The 32 gained FMCR ranged between 0.03-1.96Mb in
size (median: 0.83Mb) and contained a total of 288 known
genes with a range of 0-34 genes gained per region (median: 3
genes) (Table S3 in File S1).
Identification of known cancer genes in the FMCR
To identify known cancer genes within the deleted and
gained FMCR, the FMCR gene lists were compared to both
complete gene list from the cancer gene census project (http://
cancer.sanger.ac.uk/cancergenome/projects/census/,
accessed June, 2013), and the CRC and breast cancer driver
genes identified in a recent high throughput re-sequencing
study [34]. This analysis indicated the presence of 27 “cancer
genes” located within the deleted FMCR (~3.8% of the total
number of deleted genes; Table S2 in File S1) and 11 “cancer
genes” within the gained FMCR (~3.8% of the total number of
gained genes; Table S3 in File S1).
The occurrence of a cancer gene within an FMCR does not
necessarily imply that it is acting as a driver gene. For some
“cancer genes”, the type of FMCR (deleted or amplified) was
not consistent with the known gene function, an example being
the deletion of the known oncogene NRAS. However, the gene
function and the type of the FMCR were often consistent with
expectation, examples including deletions of MAP2K4 and
CDKN2C (Table S2 in File S1) and gain of FGFR1 (Table S3 in
File S1). Perhaps, most importantly, the classical SMAD4
tumour suppressor deletion and oncogenic MYC gain were
both observed within deleted and gained FMCR respectively.
The frequency of both SMAD4 deletions and MYC gains in the
45 chromosomally unstable cases was high at ~53% (Tables
S2 & S3 in File S1).
Comparison with published SCNA data
In order to cross-validate our results with published data, we
compared the FMCR to common chromosomal aberrations of
less than 3Mb identified in four recent CRC studies
[13,16,22,35]. The total of focal aberrations identified in these
studies was 187 gains and 189 deletions. Between the 4
published studies, there were only 10 overlapping focal
deletions (5.3%) and 29 overlapping focal gains (15.5%). A
higher proportion of the FMCR in our study overlapped the
published regions. In total, 27 of our 64 deleted FMCR (42.2%)
and 11 of our 32 gained FMCR (34.4%) overlapped focal
deletions and gains in the 4 published studies.
A large SCNA study was recently performed in 26 different
cancer types, including CRC [17]. The study identified a list of
the 20 most common somatic deletions and gains across the
analysed cancer types. Moreover, a candidate driver gene was
also selected for each of the common SCNA. A comparison
between our FMCR and the most common regions in the
Beroukhim et al study revealed an overlap with 5 of the
deletion areas (25% of total) and 3 of the gain areas (15% of
total). All the candidate genes identified by Beroukhim and
colleagues in their study were contained within the overlapping
areas from our FMCR.
Pathway analysis
In order to search for any specific patterns or pathways
affected by the genes within the deleted or gained FMCR, the
Database for Annotation, Visualisation, and Integrated
Discovery (DAVID) v6.7 was used (http://
david.abcc.ncifcrf.gov/) [36]. DAVID performs enrichment
analysis (based on biological annotations for the target genes)
to identify any biological pathways that are statistically
significantly over-represented in the analysed gene list [36]. For
the deleted FMCR, the most enriched cancer-related pathway
was Apoptosis (P = 0.014) (Figure S1) with 10 apoptotic genes
occurring within the deleted FMCR. Seven of these genes
(CASP3, CASP8, CASP10, NFKBIA, CAPN1, BAD, TNF and
TNFRSF1A) have pro-apoptotic roles and 3 (PIK3R5, PIK3R2
and CFLAR) are anti-apoptotic. Also, the p53 signalling
pathway was enriched in the deleted regions (P = 0.079) with 5
affected genes (Figure S2); CCNB1, GADD45G, SERPINE1,
SESN2 and SFN, all of which have reported anti-survival
functions.
On the other hand, the oncogenic MAPK signalling pathway
was the most over-represented pathway in the gained FMCR
(P = 0.032) with 9 affected genes (Figure S3). Seven of these
genes (CACNA1H, FGF23, FGF6, FGFR1, MAPKAPK2, ELK4
and MYC) are known to have growth promoting and survival
functions, while the other 2 (DUSP8 and DUSP2) have anti-
survival functions.
Gene Relationships Among Implicated Loci (GRAIL) analysis
was also performed (http://www.broadinstitute.org/mpg/grail/)
[37] to search for functional relationships among the genomic
regions. The terms apoptosis, apoptotic and caspase were
among the most significantly enriched amongst the deleted
FMCR. For the gains, potassium conductance channels and
the hedgehog pathways were among the most significantly
enriched terms.
Identification of candidate driver genes within
candidate FMCR
In order to identify novel candidate CRC driver genes, the
FMCR criteria were made more stringent. Candidate FMCR
were selected if they were defined by 4 SDE, occur in ≥20% of
the cases and have a maximum of 12 genes within 3.0Mb of
size. These more stringent FMCR definitions identified 11
deletions (Table 1) and 8 gains (Table 2). Out of the 28 genes
within the deleted areas, 10 (35.7%) were identified as
candidate driver genes with known or potential tumour
suppressor functions and out of the 31 genes within the gained
regions, 6 (19.4%) were candidates with known or potential
oncogenic function (Tables 1 and 2; see Discussion).
Candidate tumour suppressor genes in deleted FMCR included
RASSF3, IFNAR1, IFNAR2 and NFKBIA, and candidate
oncogenes in gained FMCR included PRDM16, TNS1, RPA3
and KCNMA1. Importantly, the copy number status of 2 of
these novel candidate driver genes, NFKBIA and KCNMA1,
was confirmed by specific quantitative RT-PCR assays.
Candidate Driver Genes in Colorectal Cancer
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Discussion
Identification of FMCR and affected pathways
The frequency and pattern of mutations in APC, TP53,
KRAS, BRAF and PIK3CA were typical of MSS/CIN tumours,
suggesting that the sample analysed here is representative of
this tumour type. FMCR were initially defined as aberrant
regions smaller than 3Mb in size, occurring in more than 10%
of the cases, with at least 2 SDE and a COCA score ~ ≥2 (p-
value = 0.01). Overall, 64 deleted and 32 gained FMCR were
identified according to these criteria. The previously published
studies showed a rather low level of overlap of aberrations
between them (5.3% for focal deletions and 15.5% for focal
gains) [13,16,22,35]. This is perhaps not surprising since the
use of different platforms, analytical methods and sample sets
will result in the identification of different hotspots of
aberrations. Our study showed a higher degree of overlap with
the previously published data (42.2% of deleted FMCR and
34.4% of gained FMCR), suggesting the absence of any
significant levels of bias in our sampling and methods.
Pathway analysis showed that the most significantly enriched
cancer-related pathways amongst deleted FMCR were
apoptosis and p53 signalling pathways. Ten apoptotic genes
were commonly deleted in our samples, 7 of which have known
pro-apoptotic functions and 3 (PIK3R2, PIK3R5 and CFLAR)
have anti-apoptotic roles. Nevertheless, CFLAR occurs within
the same FMCR as the pro-apoptotic genes CASP8 and
CASP10. Similarly, PIK3R5 is located 1.2Mb downstream of
TP53, and 81% (n=17) of the deletions are common between
the 2 genes. Therefore, it seems likely that it is the deletion of
the pro-apoptotic genes within the FMCR which is acting as a
driver event, with the anti-apoptotic genes being co-deleted
passengers. For the p53 signalling pathway, all the deleted
genes (n=5) are known to have anti-tumourigenic activities. It is
notable that TP53 itself was also deleted in 37.8% (n=17) of the
cases, but it was not identified within an FMCR. These results
suggest that the deleted FMCR might play an important role in
tumour cell survival through disabling apoptosis and/or the p53
signalling pathway. Moreover, the enrichment of apoptotic
genes within the deleted FMCR supports the known correlation
between genomic instability and defective apoptosis [38].
The most significantly enriched pathway for the gained
FMCR genes was the oncogenic MAPK pathway, with 9 genes
being commonly affected. Seven of these genes are known or
predicted to have oncogenic activities by promoting tumour
growth and survival. Although, 2 genes have anti-survival roles,
one of these (DUSP8), occurred within the same FMCR as the
oncogenic growth-promoting gene IGF2. Overall these results
Table 1. Candidate driver genes in deleted FMCR.
Chromosomal location Start End Size (Mb) Recurrence (%) SDE Genes Candidate genes*
3p14.3 57521404 57652691 0.13 24.44 4 3  
3p14.2 60078018 61195823 1.12 31.11 7 1 FHIT
4q22.1 91340468 92674544 1.33 33.33 8 2 TMSL3
6q26 162357125 163049854 0.69 22.22 7 1 PARK2
11p15.4 9172449 9363610 0.19 22.22 5 3  
12q14.2 63277389 63368109 0.09 20.00 4 1 RASSF3
14q13.2 34108596 34950339 0.84 28.89 5 9 NFKBIA
16p13.3-p13.2 6132536 7018275 0.89 24.44 7 1 A2PB1
17p13.1-p12 10957541 12400968 1.44 48.89 5 3 MAP2K4
20p12.1 14376202 16071135 1.69 37.78 10 1 MACROD2
21q22.11 33554005 33651205 0.10 28.89 7 3 IFNAR1, IFNAR2
* Candidate genes defined based on cancer-relevant functions.
doi: 10.1371/journal.pone.0083859.t001
Table 2. Candidate driver genes in gained FMCR.
Chromosomal location Start End Size (Mb) Recurrence (%) SDE Genes Candidate genes*
1p36.32 2412144 3630036 1.22 26.67 7 11 PRDM16
1p34.3 36881028 37535891 0.65 20.00 5 1  
2q35 218354227 218556081 0.20 20.00 5 1 TNS1
7p22.1-p21.3 7033162 7829887 0.80 48.89 5 4 RPA3
8q23.3 113827791 114547454 0.72 51.11 4 0 NA
10q22.3 78238542 79084656 0.85 20.00 4 1 KCNMA1
12p13.32-p13.31 4282429 5364999 1.08 40.00 4 12 FGF23, FGF6
22q11.21 18517833 18686313 0.17 20.00 4 1  
* Candidate genes defined based on cancer-relevant functions.
doi: 10.1371/journal.pone.0083859.t002
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confirm that focal deletions and copy number gains target
genes within tumour suppressor and oncogenic pathways
respectively.
Candidate cancer driver genes
In total, the identified FMCR contained ~1000 genes. In order
to identify a set of candidate driver genes, the FMCR were
further prioritized by use of a more stringent FMCR definition.
The shortlisted candidate FMCR were 11 deletions and 8
gains, containing a total of 59 affected genes.
Ten of the 28 genes (35.7%) in the 11 candidate deleted
FMCR are cancer-related with known or potential tumour
suppressor function. Six of these genes (FHIT, TMSL3,
PARK2, A2BP1, MACROD2 and MAP2K4) have been
consistently reported as deleted in CRC and other cancers
[17,22,26,35]. On the other hand, RASSF3, IFNAR1, IFNAR2
and NFKBIA were not previously reported to be affected in
CRC. RASSF3 was previously shown to inhibit cell proliferation
in breast cancer cell lines [39]. Protein levels of interferon
receptors genes (IFNAR1 and 2) were shown to be down-
regulated in bladder cancer, and associated with advanced
stage and resistance to chemotherapy [40]. Inactivating
mutations of NFKBIA have been found in Hodgkin lymphoma,
and heterozygous NFKBIA deletions were reported in ~25% of
GBM cases [23,41].. Based on their functions, the literature
and their occurrence within the candidate deleted FMCR, we
propose RASSF3, IFNAR1, IFNAR2 and NFKBIA as novel
candidate CRC tumour suppressor genes.
Six of the 31 genes (19.4%) in the 8 candidate gained FMCR
are cancer related with predicted oncogenic functions
(PRDM16, TNS1, RPA3, KCNMA1, FGF23 and FGF6). FGF23
and FGF6 have been reported as gained in CRC and other
cancer types [15,17]. However, PRDM16, TNS1, RPA3 and
KCNMA1 have not been previously reported in CRC. PR
domain-containing 16 gene (PRDM16) is a known oncogene
implicated in acute myeloid leukaemia (AML) and
osteosarcoma [42,43] Tensin 1 gene (TNS1) is the only gene
present in the relevant FMCR, and TNS1 overexpression in
vitro was previously shown to significantly promote cell
migration in fibroblasts [44]. Replication protein A3 gene
(RPA3) was recently shown to be gained in metastatic
melanoma (within an FMCR) and to play an essential role in
tumour invasion [45]. Large conductance calcium-activated
potassium channel alpha subunit gene (KCNMA1), the only
gene in its FMCR, has been shown to be gained in prostate
cancer cases and overexpressed in metastatic breast cancer
[46,47]. Based on their functions, the literature and the
occurrence within the candidate gained FMCR, we propose
PRDM16, TNS1, RPA3 and KCNMA1 as novel candidate CRC
oncogenes.
In summary, our results, based on the analysis of focal
minimal common regions, confirm previously reported CRC loci
and support the hypothesis that recurrent focal aberrations
target cancer-related genes and pathways. Moreover, focal
deletions and amplifications were shown to affect known
tumour suppressor genes and oncogenes respectively. We
propose here several novel candidate CRC driver genes.
Further validation and functional studies are required to
determine their potential role in CRC tumourigenesis.
Supporting Information
Figure S1.  Apoptotic genes in the deleted FMCR (DAVID
output). DAVID output showing the apoptosis signalling
pathway with deleted genes marked by a red star.
(TIF)
Figure S2.  P53 signalling pathway in the deleted FMCR
(DAVID output). DAVID output showing the P53 signalling
pathway, with deleted genes marked by a red star.
(TIF)
Figure S3.  MAPK pathway in the gained FMCR (DAVID
output). DAVID output showing the MAPK signalling pathway
with amplified genes marked by a red star.
(TIF)
Materials and Methods S1.  Summary of the patients and
tumour characteristics, primers sequences and annealing
temperatures and NCBI gene accession numbers.
(DOC)
File S1.  Tables S1-S3. Table S1: Summary of the molecular
features of the 53 tumour samples. Table S2: Summary of the
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